Cytokinetics Inc (CYTK)

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

GlobeNewswire Inc.

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

GlobeNewswire Inc.

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Cytokinetics Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire Inc.

Cytokinetics to Hold Annual Meeting of Stockholders

GlobeNewswire Inc.

Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?

Zacks Investment Research

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

GlobeNewswire Inc.

Cytokinetics to Announce First Quarter Results on May 8, 2024

GlobeNewswire Inc.

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

GlobeNewswire Inc.

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

GlobeNewswire Inc.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

GlobeNewswire Inc.

2 Incredible Growth Stocks to Buy Right Now

The Motley Fool

Cytokinetics to Participate in March Investor Conferences

GlobeNewswire Inc.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag

MarketWatch

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

GlobeNewswire Inc.

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

Cytokinetics Reports Fourth Quarter 2023 Financial Results

GlobeNewswire Inc.

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

GlobeNewswire Inc.

Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire Inc.

Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga

Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?

Zacks Investment Research

Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program

GlobeNewswire Inc.

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

GlobeNewswire Inc.

Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024

GlobeNewswire Inc.

Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024

Zacks Investment Research

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

Zacks Investment Research

Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst

Benzinga

Wall Street Breakfast Podcast: EV Names Fall As Hertz Hits The Gas Pedal

Seeking Alpha

Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday

Benzinga

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

Zacks Investment Research

GSK to buy asthma drug developer for up to $1.4 billion in pipeline push

MarketWatch

CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday

Benzinga

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

2 Biotechs That Could Get Bought Out in 2024

The Motley Fool

Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch

Benzinga

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Zacks Investment Research

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Zacks Investment Research

Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday

Benzinga

Company News for Dec 28, 2023

Zacks Investment Research

Dow Jones posts record close as stocks end mostly higher

MarketWatch

Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher

Benzinga